HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

dihydroquinghaosu (dihydroartemisinin)

Subscribe to New Research on dihydroquinghaosu

derivative of antimalarial drug quinghaosu; structure in first source

Also Known As:

dihydroartemisinin; artemisinin, dihydro-; dihydroartemisinine; dihydroqinghaosu; dihydroquinghaosu, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12alpha,12aR*))-isomer; dihydroquinghaosu, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12alpha,12aR*))-isomer; quinghaosu, dihydro-

Networked: 368 relevant articles (60 outcomes, 81 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58

Experts

1.	White, Nicholas J: 26 articles (10/2015 - 04/2002)
2.	Dorsey, Grant: 17 articles (01/2015 - 01/2007)
3.	Nosten, François: 14 articles (10/2015 - 01/2007)
4.	Tarning, Joel: 14 articles (10/2015 - 09/2011)
5.	Kamya, Moses R: 13 articles (01/2015 - 01/2007)
6.	Rosenthal, Philip J: 12 articles (08/2015 - 01/2007)
7.	Davis, Timothy M E: 12 articles (06/2012 - 01/2002)
8.	Kakuru, Abel: 11 articles (01/2015 - 01/2009)
9.	Batty, Kevin T: 11 articles (10/2014 - 01/2002)
10.	Ilett, Kenneth F: 11 articles (06/2012 - 01/2002)

Related Diseases

1.	Falciparum Malaria (Plasmodium falciparum Malaria) 07/01/2007 - "Clinical efficacy of high dose monotherapy of oral dihydroartemisinin in uncomplicated falciparum malaria in viet nam." 01/01/2002 - "A combination of dihydroartemisinin and naphthoquine is effective for the treatment of patients with falciparum malaria." 01/01/2002 - "To observe the therapeutic efficacy of dihydroartemisinin combined with naphthoquine phosphate in patients with falciparum malaria. " 08/01/1998 - "We conclude that the three formulations of dihydroartemisinin produced and formulated in different countries were safe and effective in treating uncomplicated falciparum malaria acquired in Thailand." 08/01/1998 - "We compared the safety and efficacy of three formulations of dihydroartemisinin for the treatment of acute uncomplicated falciparum malaria in patients who received a total dose of 600 mg dihydroartemisinin over 5 days. "
2.	Malaria 04/01/2008 - "Overall efficacy of single-dose dihydroartemisinin treatment in asplenic mice was similar to intact mice although the rate of recrudescence in asplenic mice was significantly greater than intact mice at 30 and 100 mg/kg. The asplenic murine malaria model could be used in pre-clinical studies of splenic function and clearance of malaria parasites, pathophysiological studies or antimalarial drug efficacy in asplenia." 04/01/2008 - "The aim of this study was to evaluate the efficacy of dihydroartemisinin in an asplenic murine malaria model. " 09/01/1998 - "1. The clearance of dihydroartemisinin (DHA) in control and malaria-infected (MI) rats was investigated using the isolated perfused rat liver (IPRL) model and hepatic microsomal studies. " 01/01/2013 - "The aim of this study was to develop a mechanism-based growth model (MBGM) for Plasmodium berghei and then characterize the parasiticidal effect of dihydroartemisinin (DHA) in murine malaria (MBGM-PK-PD). " 08/01/2011 - "Pharmacokinetic data for CQ in animal models are limited; thus, we conducted a three-part investigation, comprising (i) pharmacodynamic studies of CQ and CQ plus dihydroartemisinin (DHA) in Plasmodium berghei-infected mice, (ii) pharmacokinetic studies of CQ in healthy and malaria-infected mice, and (iii) interspecies allometric scaling for CQ from 6 animal and 12 human studies. "
3.	Infection 05/01/2013 - "Dihydroartemisinin at a single oral dose of 300 mg/kg was given to mice on Days 14 or 16, 18, 20, 21, 22, 24, 26 or 28 post-infection, to assess the efficacy of dihydroartemisinin against juvenile S. " 05/01/2014 - "mansoni, administration with dihydroartemisinin at a single dose of 300 mg/kg on days 1, 7, 14, 21, 28, 35, 42, 49, or 56 post-infection results in total worm burden reductions of 13.8-82.1% and female worm burden reductions of 13-82.8%, and a clear-cut dose-response relationship of dihydroartemisinin against the schistosomula and adult worms of S. " 05/01/2014 - "It has been recently found that administration of dihydroartemisinin at a single dose of 300 mg/kg 2 h or 3, 5, 7, 10, 14, 18, 21, 28, or 35 days post-infection reduces total worm burdens by 1.1-64.8% and female worm burden reductions by 11.9-90.5%, and the in vivo activity of dihydroartemisinin against S. " 01/01/2014 - "japonicum were treated with dihydroartemisinin at a single oral dose of 300 mg/kg given once on each of 35-36 post-infection days, while infected but untreated mice served as controls. " 05/01/2013 - "An oral dose of dihydroartemisinin of 300 mg/kg was given to mice on Days 14, 16, 18, 20, 21, 22, 24, 26 or 28 days post-infection; this resulted in a 65.0-82.4% reduction in total worm burden and a 70.9-83.0% female worm burden. "
4.	Vivax Malaria 09/01/2007 - "Dihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria. " 01/01/2013 - "This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries. " 01/01/2013 - "Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies." 11/01/2011 - "We conducted a randomized controlled study to compare the efficacy and the tolerability of CQ and dihydroartemisinin-piperaquine (DP) in 500 adults and children with acute vivax malaria on the Northwestern border of Thailand. " 01/01/2014 - "The first 80 volunteers with slide-confirmed Plasmodium falciparum or vivax malaria were randomized 1:1 to receive either regimen (total dose 360 mg dihydroartemisinin and 2880 mg piperaquine) and followed weekly for up to 6 months. "
5.	Cerebral Malaria 10/08/2015 - "NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria." 01/01/2013 - "Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model." 10/08/2015 - "Hybrid products in which the dihydroartemisinin scaffold is combined with NO-donor furoxan and NONOate moieties have been synthesized and studied as potential tools for the treatment of cerebral malaria (CM). " 07/01/2013 - "Although 100% of untreated mice infected with Plasmodium berghei died with specific signs of cerebral malaria and 100% of mice treated with 3 mg/kg dihydroartemisinin, the active metabolite of artesunate, which is used as the first-line treatment for severe malaria, also died but showed no specific signs of cerebral malaria, 78% of mice treated with 10 mg/kg Proveblue (methylene blue) and 78% of mice treated with a combination of 3 mg dihydroartemisinin and 10 mg/kg Proveblue survived and showed no specific signs of cerebral malaria or detectable parasites."

Related Drugs and Biologics

1.	piperaquine
2.	artemether
3.	lumefantrine
4.	artesunate
5.	Mefloquine (Lariam)
6.	Primaquine
7.	artemisinine (artemisinin)
8.	sulfadoxine-pyrimethamine (Fansidar)
9.	Amodiaquine (Camoquin)
10.	Quinine (Quinson)

Related Therapies and Procedures

1.	Chemoprevention
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Oral Administration
5.	Heterologous Transplantation (Xenotransplantation)